| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| OPTIMIND PHARMA Aktie jetzt für 0€ handeln | |||||
| 24.07. | Optimind Pharma Corp: Optimind Pharma adopts semi-annual financial reporting | 2 | Stockwatch | ||
| 24.07. | Optimind Pharma Corp.: Optimind Pharma Announces Adoption of Semi-Annual Reporting | 363 | Newsfile | Toronto, Ontario--(Newsfile Corp. - July 24, 2026) - Optimind Pharma Corp. (CSE: OMND) ("Optimind" or the "Company") announces that it has elected to voluntarily adopt semi-annual financial reporting... ► Artikel lesen | |
| 11.09.25 | CSE Bulletin: Halted for Fundamental Change - Optimind Pharma Corp. (OMND) | 404 | Newsfile | Toronto, Ontario--(Newsfile Corp. - Le 11 septembre/September 2025) - Trading in the shares of Optimind Pharma Corp. (OMND) will remain halted pending receipt and review of acceptable documentation... ► Artikel lesen | |
| 08.09.25 | Optimind Pharma Corp.: Optimind Pharma Announces Definitive Agreement for Proposed Change of Business with InterviewDesk | 587 | Newsfile | Toronto, Ontario--(Newsfile Corp. - September 8, 2025) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") is pleased to announce that it has entered into a binding definitive share... ► Artikel lesen | |
| 04.09.25 | Optimind Pharma Corp.: Optimind Pharma Announces Termination of Letter of Intent | 669 | Newsfile | Toronto, Ontario--(Newsfile Corp. - September 4, 2025) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") announces that its previously announced non-binding letter of intent dated... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 40,105 | -0,09 % | Novo Nordisk: Bittere Pille | Der dänische Biopharma-Riese hat mit den Zahlen zum zweiten Quartal zwar die Prognosen für den Umsatz und den operativen Gewinn erhöht. Im Detail sorgte Novo Nordisk allerdings erneut für eine Enttäuschung... ► Artikel lesen | |
| AURORA CANNABIS | 3,274 | -0,91 % | XFRA 21P: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAURORA CANNABIS... ► Artikel lesen | |
| CANOPY GROWTH | 0,860 | -1,15 % | Will Canopy Growth Get Acquired? | ||
| BIOTEST | 33,200 | 0,00 % | Osborne Clarke berät Grifols S.A. bei der Umwandlung der Biotest AG in eine GmbH & Co. KGaA | ||
| DIGICANN VENTURES | 0,003 | -40,00 % | XFRA VY3: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| SINOPHARM | 1,818 | -1,65 % | SINOPHARM (01099): NOTICE OF BOARD MEETING | ||
| CSPC PHARMA | 0,996 | +4,37 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - CHANGE OF TRUSTEE OF THE 2018 SHARE AWARD SCHEME | ||
| TONIX PHARMACEUTICALS | 10,450 | +0,38 % | Tonix Pharma auf Canaccord-Genuity-Konferenz: Markteinführung gewinnt an Dynamik | ||
| ORAMED PHARMACEUTICALS | 3,770 | +2,17 % | ORAMED PHARMACEUTICALS INC. - 10-Q, Quarterly Report | ||
| AXSOME THERAPEUTICS | 191,15 | +2,58 % | Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues | ||
| ADASTRA | 0,116 | -100,00 % | CSE Bulletin: Suspensions - Adastra Holdings Ltd., CAT Strategic Metals Corporation, Greenrise Global Brands Inc., StickIt Technologies Inc. | Le 12 mai/May 2026
Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 5,700 | -1,72 % | Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates | Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval Strengthened... ► Artikel lesen | |
| ALTIMMUNE | 2,485 | -2,55 % | Altimmune, Inc: Altimmune Announces Second Quarter 2026 Financial Results and Business Update | Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 10,950 | +6,83 % | SELLAS Life Sciences Group, Inc. - 8-K, Current Report | ||
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership... ► Artikel lesen |